share_log

開拓藥業-B：自願公告 GT20029治療男性脫髮中國II期臨床試驗達到主要終點

KINTOR PHARMA-B: VOLUNTARY ANNOUNCEMENT PHASE II CLINICAL TRIAL OF GT20029 FOR TREATMENT OF ANDROGENETIC ALOPECIA IN CHINA REACHED PRIMARY ENDPOINT

Hong Kong Stock Exchange ·  Apr 21 06:17
Summary by Moomoo AI
開拓藥業-B（開拓藥業有限公司）宣布其自主研發的GT20029治療男性脫髮的中國II期臨床試驗達到主要研究終點，並顯示出統計學意義和臨床意義，安全性和耐受性良好。該試驗為多中心、隨機、雙盲、安慰劑對照研究，由復旦大學附屬華山醫院楊勤萍教授領導，共納入180例男性脫髮患者。GT20029在治療12周後，與安慰劑相比，顯示出顯著的毛髮增長效果。公司計劃基於這些結果進行後續的臨床策略，包括開展中國III期和美國II期臨床試驗。GT20029是基於公司自有PROTAC平臺開發的全球首個皮科外用新型AR降解劑，並計劃用於治療脫髮和痤瘡。公司提醒股東及潛在投資者，無法確保GT20029能成功開發及最終成功銷售，買賣股份時應審慎行事。
開拓藥業-B（開拓藥業有限公司）宣布其自主研發的GT20029治療男性脫髮的中國II期臨床試驗達到主要研究終點，並顯示出統計學意義和臨床意義，安全性和耐受性良好。該試驗為多中心、隨機、雙盲、安慰劑對照研究，由復旦大學附屬華山醫院楊勤萍教授領導，共納入180例男性脫髮患者。GT20029在治療12周後，與安慰劑相比，顯示出顯著的毛髮增長效果。公司計劃基於這些結果進行後續的臨床策略，包括開展中國III期和美國II期臨床試驗。GT20029是基於公司自有PROTAC平臺開發的全球首個皮科外用新型AR降解劑，並計劃用於治療脫髮和痤瘡。公司提醒股東及潛在投資者，無法確保GT20029能成功開發及最終成功銷售，買賣股份時應審慎行事。
Breakthrough Pharmaceutical-B (Pioneer Pharmaceuticals Co., Ltd.) announces that its independently developed China Phase II clinical trial for the treatment of male hair loss GT20029 has reached the main research end and demonstrated statistical and clinical significance, good safety and tolerability. The trial was a multi-center, randomized, double-blind, placebo-controlled study led by Professor Yang Qin-ping, Huashan Hospital, Fudan University, and included 180 male hair loss patients. GT20029 showed significant hair growth effects after 12 weeks of treatment compared to placebo. THE COMPANY PLANS TO PURSUE A FOLLOW-UP CLINICAL STRATEGY BASED ON THESE RESULTS, INCLUDING PHASE III CLINICAL TRIALS IN CHINA AND PHASE II IN THE UNITED STATES. GT20029 is the world's first new topical AR degradation agent developed on the basis of the company's proprietary PROTAC platform and is planned to be used to treat hair loss and acne. The Company reminds shareholders and potential investors that GT20029 cannot ensure the successful development and eventual sale of GT20029. It should exercise caution when buying and selling the shares.
Breakthrough Pharmaceutical-B (Pioneer Pharmaceuticals Co., Ltd.) announces that its independently developed China Phase II clinical trial for the treatment of male hair loss GT20029 has reached the main research end and demonstrated statistical and clinical significance, good safety and tolerability. The trial was a multi-center, randomized, double-blind, placebo-controlled study led by Professor Yang Qin-ping, Huashan Hospital, Fudan University, and included 180 male hair loss patients. GT20029 showed significant hair growth effects after 12 weeks of treatment compared to placebo. THE COMPANY PLANS TO PURSUE A FOLLOW-UP CLINICAL STRATEGY BASED ON THESE RESULTS, INCLUDING PHASE III CLINICAL TRIALS IN CHINA AND PHASE II IN THE UNITED STATES. GT20029 is the world's first new topical AR degradation agent developed on the basis of the company's proprietary PROTAC platform and is planned to be used to treat hair loss and acne. The Company reminds shareholders and potential investors that GT20029 cannot ensure the successful development and eventual sale of GT20029. It should exercise caution when buying and selling the shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more